Próximamentevie 6 nov 2026,
Combinatorial protein engineering for gene therapy and affinity protein applications
Proteínas diseñadas a medida que guían las terapias génicas hacia células específicas y ayudan a purificarlas durante su fabricación.
La defensa
De la agenda de KTH Royal Institute of Technology
- Cuándo
- vie 6 nov 2026, 90 min
- Dónde
- KTH Royal Institute of Technology, Suecia
- Campos
- Dirección
- Johan RockbergProteinteknologidblp
- Codirección
- Magdalena MalmProteinteknologi
- Tribunal
- Hildegard BüningoponenteInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany
- Idioma
- inglés
- Transmisión
- en Zoom
Enlace de la emisión
Una defensa de tesis doctoral es pública: cualquiera puede verla.
Del resumen
The thesis evaluates affinity proteins for selective gene therapies and bioprocessing, using deep sequencing in phage display to identify Affibody and nanobody binders with differing kinetics and target preferences. One paper characterises two nanobodies as protease inhibitors; another expands nanobody family analysis.
For gene delivery, Affibody ligands were integrated into AAV surfaces; the vehicles selectively transduced target-expressing cells in vitro and, in vivo, reduced liver uptake while redirecting transduction. The same binders showed selective in vitro transduction as AAV ligands. Transduction may depend on epitope, kinetics and capsid integration site, so binder diversity matters.
An Affimer ligand for AAV9 chromatography matched commercial resins in recovery and quality, with milder elution. Another paper assesses plasmid purification effects on rAAV production.
Leer la tesisAnuncio de la universidad
¿Es esta tu defensa?
Escribe la página de defensa destacada: una entradilla, una cita destacada y tres preguntas. Al enviarla a revisión, reclamas la defensa como tuya.
Tomado de la agenda de KTH Royal Institute of Technology.